Finding – Page 14

Novartis Secures Temporary Block on Generic Version of Entresto

8 months ago talkbio0Tagged Entresto, generic version, Heart failure, MSN gene, Novartis, Obstruction, Transitory

Novartis, Entresto, generic version, MSN Pharmaceuticals, temporary block, heart failure drug

Hengrui and Kailera’s Obesity Drug HRS9531 Shows Promising Results in Phase 2 Trial

8 months ago talkbio0Tagged GLP-1/GIP receptor dual agonist, Hengrui Pharmaceuticals, Kailera, Obesity, Phase 2 clinical trial, Weight Loss

HRS9531, Obesity treatment, GLP-1/GIP receptor dual agonist, Phase 2 clinical trial, Weight loss, Hengrui Pharmaceuticals, Kailera Therapeutics

Leyden Labs Secures $70 Million Funding to Develop Broad Protection Against Respiratory Viruses

8 months ago talkbio0Tagged biotech, Laboratory test finding, Leyden, Mucosal Protection Platform, Nasal, Nasal defenses, PanFlu, Protection, Respiratory viruses

Leyden Labs, Respiratory viruses, Influenza, Nasal defenses, Broad protection, PanFlu, Mucosal Protection Platform, Biotech funding

LB-102: Promising Phase 2 Results Revive Benzamide Antipsychotics for Schizophrenia Treatment in the US

8 months ago talkbio0Tagged Antipsychotic Agents, benzamide, dosing, LB-102, once-daily, PANSS, Phase 2 trial, safety profile, Schizophrenia, Score

LB-102, schizophrenia, benzamide antipsychotics, Phase 2 trial, PANSS scores, safety profile, once-daily dosing

LB Pharma’s Novel Antipsychotic LB-102 Shows Promise in Phase II Schizophrenia Trial

8 months ago talkbio0Tagged benzamide antipsychotic, first-in-class, LB-102, PANSS, Phase 2 Clinical Trials, Schizophrenia, Score

LB-102, Benzamide antipsychotic, Schizophrenia treatment, Phase II clinical trial, PANSS score reduction, First-in-class potential

GLP-1 Medications: Balancing Efficacy and Concerns Amidst Celebrity Endorsements and Rising Demand

8 months ago talkbio0Tagged agonists, aspects of adverse effects, Diabetes Mellitus, Non-Insulin-Dependent, Employer, Endorsements, Famous Persons, Financial cost, Glucagon-Like Peptide 1, Health Planning, Long-term Safety, Weight Loss

GLP-1 agonists, Weight loss, Type 2 diabetes, Celebrity endorsements, Side effects, Long-term safety, Cost implications, Employer health plans

Carecode Revolutionizes Brazilian Healthcare with AI-Powered Customer Service, Secures $4.3M Funding

8 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Automation, brazilian, Carecode, Customer, Health care facility, Services

Carecode, AI, Healthcare, Customer Service, Automation, Funding, Brazilian Healthcare

CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE 1 Trial, Falling Short of 25% Target

9 months ago talkbio0Tagged cagrilintide, CagriSema, Nordisk, Obesity, Phase 3 REDEFINE 1 Trial, semaglutide, Weight Loss

CagriSema, Weight Loss, Phase 3 REDEFINE 1 Trial, Obesity Treatment, Novo Nordisk, Semaglutide, Cagrilintide

Rhythm Pharmaceuticals Secures Expanded FDA Approval for IMCIVREE to Treat Genetic Obesity in Children as Young as 2 Years Old

9 months ago talkbio0Tagged Approved, Bardet-Biedl Syndrome, Genetic obesity, Imcivree, leptin receptor, human, Obesity, PCSK1 gene, Pediatric brand name, POMC, Rhythm, setmelanotide, United States Food and Drug Administration

Rhythm Pharmaceuticals, IMCIVREE, setmelanotide, FDA approval, genetic obesity, Bardet-Biedl syndrome, POMC, PCSK1, LEPR deficiency, pediatric obesity treatment

Merck Enters Obesity Market with $2 Billion Deal for Chinese Oral GLP-1 Drug

9 months ago talkbio0Tagged Benefit, cardiometabolic, Glucagon-Like Peptide 1, Hansoh Pharma, HS-10535, Merck, Obesity, Oral cavity, Weight Loss

Merck, Obesity, Oral GLP-1, Hansoh Pharma, HS-10535, Weight Loss, Cardiometabolic Benefits